Neurology

Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis.

Muscle Nerve. 2002 Oct;26(4):549-52.
 
Wolfe GI, Barohn RJ, Foster BM, Jackson CE, Kissel JT, Day JW, Thornton CA, Nations SP, Bryan WW, Amato AA, Freimer ML, Parry GJ; Myasthenia Gravis-IVIG Study Group.

Department of Neurology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, Texas 75390-8897,USA. gil.wolfe@utsouthwestern.edu

We initiated a randomized, double-blinded, placebo-controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6-week open-label study of IVIG, positive trends were observed. Copyright 2002 Wiley Periodicals, Inc. Muscle Nerve 26: 549-552, 2002

Publication Types:
  • Clinical Trial
  • Randomized Controlled Trial

PMID: 12362423 [PubMed - indexed for MEDLINE]
Copyright © 2018 PPTA. All rights reserved. (202) 789-3100